Ordena

Cercar

01/04/2023 The immunoregulatory role of IL-35 in patients with interstitial lung disease
Osuna-Gomez, R, Barril, S, Mulet, M, Atenza, CZ, Millan-Billi, P, Pardessus, A, Brough, DE, Sabzevari, H, Semnani, RT, Castillo, D, Vidal, S. The immunoregulatory role of IL-35 in patients with interstitial lung disease. IMMUNOLOGY. 2023; 168(4)DOI:10.1111/imm.13596. PMID:36273280. IF:4.900(Q2/3D).
01/04/2023 Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry
Dobarro, D, Donoso-Trenado, V, Sole-Gonzalez, E, Moliner-Abos, C, Garcia-Pinilla, JM, Lopez-Fernandez, S, Ruiz-Bustillo, S, Diez-Lopez, C, Castrodeza, J, Mendez-Fernandez, AB, Vaqueriza-Cubillo, D, Cobo-Marcos, M, Tobar, J, Sagasti-Aboitiz, I, Rodriguez, M, Escolar, V, Abecia, A, Codina, P, Gomez-Otero, I, Pastor, F, Marzoa-Rivas, R, Gonzalez-Babarro, E, de Juan-Baguda, J, Melendo-Viu, M, de Frutos, F, Gonzalez-Costello, J. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. ESC Heart Failure. 2023; 10(2)DOI:10.1002/ehf2.14278. PMID:36655614. IF:3.200(Q2/3D).
01/04/2023 Placental site trophoblastic tumor (PSTT): a case report and review of the literature
Zampacorta, C, Pasciuto, MP, Ferro, B, Lucidi, A, Maestro, AS, Espinosa, I, D'Angelo, E, Prat, J. Placental site trophoblastic tumor (PSTT): a case report and review of the literature. Pathologica. 2023; 115(2)DOI:10.32074/1591-951X-873. PMID:37114629. IF:(Q/D).
01/04/2023 Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Perl A.E., Larson R.A., Podoltsev N.A., Strickland S., Wang E.S., Atallah E., Schiller G.J., Martinelli G., Neubauer A., Sierra J., Montesinos P., Recher C., Yoon S.-S., Maeda Y., Hosono N., Onozawa M., Kato T., Kim H.-J., Hasabou N., Nuthethi R., Tiu R., Levis M.J.. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplantation And Cellular Therapy. 2023; 29(4)DOI:10.1016/j.jtct.2022.12.006. PMID:36526260. IF:3.600(Q1/3D).